Daniel Laorden

531 total citations
21 papers, 54 citations indexed

About

Daniel Laorden is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Daniel Laorden has authored 21 papers receiving a total of 54 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Immunology. Recurrent topics in Daniel Laorden's work include Asthma and respiratory diseases (15 papers), Respiratory and Cough-Related Research (7 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). Daniel Laorden is often cited by papers focused on Asthma and respiratory diseases (15 papers), Respiratory and Cough-Related Research (7 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). Daniel Laorden collaborates with scholars based in Spain and Romania. Daniel Laorden's co-authors include Santiago Quirce, Javier Domínguez‐Ortega, Elena Villamañán, Rodolfo Álvarez-Sala, David Romero, Pablo Aguilar, Ester Zamarrón, Pilar Barranco, Paloma Oliver and Raquel Casitas and has published in prestigious journals such as Respiratory Medicine, Journal of Clinical Medicine and Journal of Asthma.

In The Last Decade

Daniel Laorden

18 papers receiving 52 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Laorden Spain 5 37 33 10 9 8 21 54
Freda Yang United Kingdom 5 75 2.0× 47 1.4× 14 1.4× 8 0.9× 2 0.3× 9 91
Eirini Roumpedaki Greece 3 19 0.5× 23 0.7× 4 0.4× 9 1.0× 2 0.3× 6 62
Erin S. Harvey Australia 4 56 1.5× 35 1.1× 9 0.9× 9 1.0× 8 63
Yoshihisa Tokunaga Japan 5 33 0.9× 38 1.2× 19 1.9× 3 0.3× 10 63
Maria Curotto de Lafaille United States 4 30 0.8× 19 0.6× 13 1.3× 17 1.9× 5 45
Neva Eleangovan Australia 2 59 1.6× 52 1.6× 11 1.1× 5 0.6× 3 67
Riyad Al‐Lehebi Saudi Arabia 5 38 1.0× 24 0.7× 5 0.5× 8 0.9× 14 61
Laurie-Anne Thion France 3 8 0.2× 12 0.4× 3 0.3× 9 1.0× 8 1.0× 4 31
Hakon Hakonarson United States 3 34 0.9× 17 0.5× 15 1.5× 2 0.2× 5 53
E. Valovirta Finland 3 44 1.2× 26 0.8× 7 0.7× 24 2.7× 3 58

Countries citing papers authored by Daniel Laorden

Since Specialization
Citations

This map shows the geographic impact of Daniel Laorden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Laorden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Laorden more than expected).

Fields of papers citing papers by Daniel Laorden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Laorden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Laorden. The network helps show where Daniel Laorden may publish in the future.

Co-authorship network of co-authors of Daniel Laorden

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Laorden. A scholar is included among the top collaborators of Daniel Laorden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Laorden. Daniel Laorden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laorden, Daniel, et al.. (2025). Efficacy Assessment of Biological Treatments in Severe Asthma. Journal of Clinical Medicine. 14(2). 321–321. 5 indexed citations
2.
Villamañán, Elena, Daniel Laorden, Leticia de las Vecillas, et al.. (2025). Adherence to Intranasal Corticosteroids in Patients with Severe Asthma and Nasal Polyposis: Pharmacological and Clinical Factors Involved. Journal of Clinical Medicine. 14(14). 5070–5070. 1 indexed citations
3.
Longas, Marı́a O., Cristina Aponte, Daniel Laorden, et al.. (2025). Long Term Effectiveness of Mepolizumab in the Treatment of Chronic Eosinophilic Pneumonia. Open Respiratory Archives. 7(3). 100462–100462.
4.
Laorden, Daniel, Javier Domínguez‐Ortega, Pablo Aguilar, et al.. (2024). Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met?. Journal of Clinical Medicine. 13(23). 7152–7152. 2 indexed citations
5.
Villamañán, Elena, Daniel Laorden, Carlos Carpio, et al.. (2024). Cardiovascular Events in Patients with Severe Asthma—A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2. Journal of Clinical Medicine. 13(15). 4299–4299. 1 indexed citations
6.
7.
8.
Laorden, Daniel, Ester Zamarrón, David Romero, et al.. (2023). Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R. Respiratory Medicine. 211. 107216–107216. 4 indexed citations
9.
Carpio, Carlos, Antonio Buño Soto, Alberto M. Borobia, et al.. (2023). Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19. Journal of Clinical Medicine. 12(19). 6299–6299. 2 indexed citations
10.
Laorden, Daniel, et al.. (2023). A real life cohort of mepolizumab treatment in severe eosinophilic asthma. European Annals of Allergy and Clinical Immunology. 56(4). 169–169. 4 indexed citations
11.
Villamañán, Elena, Daniel Laorden, David Romero, et al.. (2023). Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. Journal of Investigational Allergology and Clinical Immunology. 34(1). 60–61. 3 indexed citations
12.
Domínguez‐Ortega, Javier, et al.. (2023). Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting. Journal of Asthma. 61(1). 39–47. 2 indexed citations
13.
Laorden, Daniel, Ester Zamarrón, Javier Domínguez‐Ortega, et al.. (2022). Successful Long-Term Treatment Combining Omalizumab and Anti-IL-5 Biologics in Allergic Bronchopulmonary Aspergillosis. Archivos de Bronconeumología. 58(8). 624–626. 6 indexed citations
14.
Laorden, Daniel, et al.. (2022). Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting. Journal of Investigational Allergology and Clinical Immunology. 33(3). 217–219. 5 indexed citations
15.
Laorden, Daniel, Javier Domínguez‐Ortega, Carlos Carpio, et al.. (2022). Long COVID outcomes in an asthmatic cohort and its implications for asthma control. Respiratory Medicine. 207. 107092–107092. 9 indexed citations
16.
Villamañán, Elena, et al.. (2022). Adherence to inhalers in patients with severe asthma treated with anti-interleukin-5 biologics.. PubMed. 46(4). 203–207. 1 indexed citations
17.
Aguilar, Pablo, Daniel Laorden, María Jiménez-González, et al.. (2022). RELATIONSHIP BETWEEN KREBS VON DEN LUNGEN-6 (KL-6) LEVELS AND THE SEVERITY OF PATIENTS OF A POST-COVID MULTIDISCIPLINARY UNIT. 1203–1203.
18.
Marques‐Mejias, Andreina, et al.. (2018). Worsening of Severe Asthma Due to Menstruation and Sensitization to Albumins. Journal of Investigational Allergology and Clinical Immunology. 28(5). 330–332. 1 indexed citations
19.
Oliver, Paloma, et al.. (2018). Indicaciones e interpretación diagnóstica de la gasometría arterial. Medicine - Programa de Formación Médica Continuada Acreditado. 12(66). 3898–3902. 2 indexed citations
20.
Laorden, Daniel, et al.. (2018). Enfermedad intersticial pulmonar. Medicine - Programa de Formación Médica Continuada Acreditado. 12(67). 3909–3916. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Freda Yang Breakdown of academic impact, for papers by Eirini Roumpedaki Breakdown of academic impact, for papers by Erin S. Harvey Breakdown of academic impact, for papers by Yoshihisa Tokunaga Breakdown of academic impact, for papers by Maria Curotto de Lafaille Breakdown of academic impact, for papers by Neva Eleangovan Breakdown of academic impact, for papers by Riyad Al‐Lehebi Breakdown of academic impact, for papers by Laurie-Anne Thion Breakdown of academic impact, for papers by Hakon Hakonarson Breakdown of academic impact, for papers by E. Valovirta
Rankless by CCL
2026